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Objectives The aim of this study was to conduct an initial clinical evaluation of the new HeartWare Ventricular Assist Sys-
tem (HeartWare, Inc., Framingham, Massachusetts) in a multicenter, prospective, nonrandomized single-arm
clinical trial.
Background Heart failure is a worldwide epidemic. The effectiveness of heart transplantation and medical therapy is limited,
resulting in the emergence of mechanical circulatory support as a primary treatment for end-stage heart dis-
ease. Left ventricular assist devices that use rotary pumps are small and durable, which might reduce morbidity
and mortality during support.
Methods Fifty heart transplant candidates with New York Heart Association functional class IV symptoms were supported at 5
international centers by the HeartWare System for 180 days, until heart transplant, myocardial recovery and device
explant, or death. Patients who continue to be supported have been followed for a minimum of 2 years.
Results Of the 50 patients, 20 (40%) received transplants, 4 (8%) had the pump explanted after myocardial recovery,
and 17 (34%) continue support at 2 years. Nine (18%) patients died during support from sepsis (n  3), multiple
organ failure (n  3), or hemorrhagic stroke (n  3). The actual survival at 6, 12, and 24 months was 90%,
84%, and 79%, respectively. In the survivors, measures of quality of life showed a significant improvement over
baseline values. Significant improvements were found for recognition memory at 3 months after implant (p 
0.006). The most frequent adverse events were infection and bleeding.
Conclusions Patients with end-stage heart failure can be safely and effectively supported by the HeartWare Ventricular Assist
System with improved quality of life and neurocognitive function. (J Am Coll Cardiol 2011;57:1375–82)
© 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.10.040Heart failure is a worldwide epidemic that contributes
considerably to the overall cost of health care in developed
nations. The number of people afflicted with this complex
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accepted October 11, 2010.disease is increasing at an alarming pace—a trend that is
likely to continue for many years. Medical therapy has
limited effectiveness, with expected 1- and 5-year mortality
rates nearing 30% and 60%, respectively (1). Heart trans-
plantation is an effective treatment, but it is restricted by the
number of available donor organs. Mechanical circulatory
support with a left ventricular assist device (LVAD) is
See page 1383
emerging as a primary treatment for patients with advanced-
stage heart failure. When compared with medical therapy,
support with an LVAD as a bridge to heart transplant or for
destination therapy provides a better chance for survival
with an enhanced quality of life (2,3).
The first generation of pulsatile LVADs has been effec-
tive in supporting patients for bridge to transplant (BTT)
and destination therapy, but persistent complications related to
the size and durability of the devices have limited acceptance
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fection, and device failure have
been leading causes of morbidity
and mortality during support with
these devices. Smaller and more du-
rable rotary blood pumps have
been developed in an effort to
minimize LVAD-related compli-
cations and to broaden the popu-
lation of patients who might ben-
efit from heart assist device
therapy (5). The HeartWare Ven-
tricular Assist System (Heart-
Ware, Inc., Framingham, Massa-
chusetts) is a new mechanical
circulatory support system that is
smaller and more durable than
previous LVAD systems (6). The
small HeartWare Ventricular As-
sist Device (HVAD) pump can be placed within the pericar-
dial space, which avoids the need for abdominal surgery and
the creation of a pump pocket. Durability is enhanced by the
wearless and friction-free movement of the device’s single,
moving internal component: the impeller. The peripheral
components have been designed for ease of use by the patient
in outpatient settings. The HVAD system is intended to
provide long-term left ventricular (LV) support in patients
with advanced heart failure.
In this report, we present the results of a multicenter
clinical trial designed to evaluate the safety and efficacy of
the HVAD system to support patients with end-stage heart
failure.
Methods
Study design. This multicenter, prospective, nonrandom-
ized, single-arm trial was designed to evaluate the safety and
efficacy of the HVAD system when used as a bridge to heart
transplant. Patients with end-stage heart failure who were
eligible for cardiac transplantation were candidates for the
study. The study inclusion and exclusion criteria are listed in
the Online Appendix. Fifty patients were enrolled between
March 2006 and December 2008 at 5 medical centers in
Europe (3) and Australia (2). The dates of follow-up for
adverse events were from March 22, 2006, through June 3,
2009. Adverse events were collected until all 50 patients
reached end point. Patients who remain on support have been
followed for status only up to a minimum of 24 months. The
study was in compliance with U.S. Food and Drug Adminis-
tration guidelines and was approved by the ethics committee
(institutional review board) at each of the participating centers.
All patients gave informed consent.
End points. The primary study end point was survival to
transplant, cardiac recovery with device explant, or continu-
ing device support at 180 days. Secondary end points
Abbreviations
and Acronyms
BTT  bridge to transplant
HVAD  HeartWare
Ventricular Assist Device
INR  international
normalized ratio
KCCQ  Kansas City
Cardiomyopathy
Questionnaire
LV  left ventricle/
ventricular
LVAD  left ventricular
assist device
RVAD  right ventricular
assist device
SHFM  Seattle Heart
Failure Modelincluded a comparison of baseline cardiac index to the meanpump flow index (pump flow/body surface area) and the
incidence of all adverse events and device failures as defined
by the INTERMACS registry (Inter-Agency Registry for
Mechanically Assisted Circulatory Support) (7). Measures
for quality of life (Kansas City Cardiomyopathy Question-
naire [KCCQ]) and neurocognitive function (neurocogni-
tive evaluations included 4 standard neurocognitive mea-
sures with 8 procedures and surveyed cognitive domains
such as verbal learning, memory, knowledge of visually
presented drawings, cognitive speed, and visual spatial
abilities) were obtained at baseline and at 1, 3, and 6 months
of support. Under the direction of the site investigators, data
were collected and then submitted to a contracted clinical
research organization for analysis. All data were analyzed
and adjudicated by a Clinical Events Committee and Data
Safety and Monitoring Board. The Seattle Heart Failure
Model (SHFM) was used to generate a virtual control arm
with the baseline clinical parameter obtained within 1 week
before implantation.
HVAD system. The implanted components of the HVAD
system comprise the HVAD blood pump with integrated
inflow cannula, an outflow graft, and a percutaneous drive-
line. The HVAD pump weighs 140 g, has a displacement
volume of 50 ml, and has an external diameter of 53 mm.
The pump operates within the range of 1,800 to 4,000 rpm
and can pump up to 10 l/min of blood. Within the titanium
pump housing is a single moving component, the impeller,
which is suspended by magnetic and hydrodynamic forces
for frictionless rotation. Communication from the pump to
the external power and control components is provided by a
flexible, polyurethane-covered driveline that is externalized
through the abdominal wall. A microprocessor-based con-
troller monitors pump function and regulates power to dual
motors within the pump. The controller displays pump
speed, blood flow rate, power, alarm conditions, and in-
structions for resolving alarm conditions. A continuous
power supply is provided by either AC or DC sources,
including lithium-ion batteries for portable operation. A
system monitor provides a means for adjusting pump
operating parameters, monitoring pump function and stor-
ing data.
During the study period, the HVAD pump was im-
planted through a median sternotomy and with normother-
mic cardiopulmonary bypass. A sewing-ring made of Da-
cron and titanium was sewn onto the epicardial surface of
the heart at the apex of the LV. An opening into the LV was
made through the center of the sewing-ring by using a circular
coring knife, after a cruciate incision. The 21-mm integrated
inflow cannula of the pump was then inserted into the LV
through the opening in the sewing ring and secured in place by
tightening the C-ring portion of the sewing cuff. The 10-mm
outflow graft was trimmed to the proper length and anasto-
mosed to the ascending aorta. The pump was positioned
within the pericardial space at the apex of the heart, and the
driveline was externalized through the right upper quadrant
of the abdomen (Fig. 1). After air was removed from the
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nary bypass, and HVAD pump support was initiated. Pump
speed was adjusted to achieve the desired level of cardiac
output.
Continuous anticoagulation therapy is recommended for
patients with HVAD pumps, but therapy is individualized
for each patient. In this study, patients were given an
intravenous heparin infusion after risk of surgical bleeding
had passed to increase activated partial thromboplastin time
to a target range of 50 to 60 s or an activated clotting time
of 140 to 160 s. Once patients were able to take oral
medications, warfarin and aspirin or clopidogrel were given
and continued throughout support. Warfarin of each patient
was adjusted toward a targeted international normalized
ratio (INR) value between 2.0 and 3.0. Cardiac function was
supported with inotropic medications, by managing fluid
volume, and adjusting the speed of the HVAD pump
between 2,400 and 3,200 rpm to achieve a cardiac index
2.0 l/min/m2. After they recovered from the implant
surgery, patients received rehabilitative care and education
about the HVAD system. Once the patients were clinically
stable, had demonstrated their ability to provide self-care,
and were able to maintain the HVAD system properly, they
were discharged from the hospital.
Statistical analyses. Statistical differences of continuous
variables between baseline and post-implant data were
determined by a paired t test with a significance level of
0.05. Hemodynamic and biochemical data are presented as
the mean  SD. Measures of quality of life and neurocog-
nitive function are reported for patients who received
evaluations before implantation and at 1 month and 3 and 6
Figure 1 HVAD Pump Positioned in Pericardial Space
Position of the HeartWare Ventricular Assist Device (HVAD) pump
(HeartWare, Inc., Framingham, Massachusetts) after implantation.months after implant. The testing was not completed for all
epatients at all time intervals, therefore repeated measures
analysis of variance was used to evaluate change across
testing sessions for group data. Patients were included in the
repeated measures analyses of variance if they had complete
data for the specific time points being reported. Quality of
life and neurocognitive function data are given as the mean
and SEM. Competing outcomes data were calculated with
actual percentages for each outcome, because all ongoing
patients were followed for a minimum of 24 months.
Baseline CharacteristicsTable 1 Baseline Characteristics
Age (yrs) 48.5 (20–75)
Sex, male 43 (86%)
BSA (m2) 1.9 (1.4–2.6)
BMI (kg/m2) 25.6 (16.5–40.8)
Heart failure etiology
Idiopathic CMP 22 (44%)
Ischemic CMP 20 (40%)
Familial or congenital CMP 5 (10%)
Myocarditis 3 (6%)
INTERMACS profile
Profile 2 11 (22%)
Profile 3 35 (70%)
Profile 4 4 (8%)
Inotropic support 50 (100%)
Intra-aortic balloon pump 4 (8%)
LVEF (%) 18.7 5.9
LVEDD (mm) 68.6 8.0
Cardiac index (l/min/m2) 1.94 0.54
PCWP (mm Hg) 23.7 6.5
CVP (mm Hg) 12.3 5.9
Heart rate (beats/min) 89.1 20.2
Arterial blood pressure (mm Hg)
Systolic 101.5 13.9
Diastolic 64.2 10.9
Mean 76.7 10.6
Pulmonary artery pressure (mm Hg)
Systolic 47.6 15.7
Diastolic 27.7 9.3
Laboratory values
BUN (mg/dl) 28.9 15.6
Creatinine (mg/dl) 1.3 0.5
ALT (IU/l) 63.5 127
AST (IU/l) 75.8 132
LDH (IU/l) 316 159
Total bilirubin (mg/dl) 1.5 1.0
Hgb (g/dl) 12.5 2.0
HCT (%) 36.8 6.0
PFH (mg/dl) 10.1 13.8
Platelets (109/l) 243 101
INR 1.6 0.6
APTT (s) 39.7 10.6
Values are median (range), n (%), or mean  SD.
ALT  alanine aminotransaminase; APTT  activated partial thromboplastin time; AST 
spartate aminotransaminase; BMI  body mass index; BSA  body surface area; BUN  blood
urea nitrogen; CMP  cardiomyopathy; CVP  central venous pressure; HCT  hematocrit; Hgb 
hemoglobin; INR  international normalized ratio; INTERMACS  Inter-Agency Registry for
Mechanically Assisted Circulatory Support; LDH  lactic dehydrogenase; LVEDD  left ventricular
nd-diastolic dimension; LVEF  left ventricular ejection fraction; PCWP  pulmonary capillary
wedge pressure; PFH  plasma-free hemoglobin.
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Ware patients with the SHFM estimated survival with
medical therapy were analyzed with the Kaplan-Meier
actuarial survival method and the SHFM (8). An estimated
LVAD hazard ratio for benefit was calculated with the
SHFM estimated survival and the Kaplan Meier observed
survival. The p value was derived with a Z test. Multiple
comparisons were made without correction for multiplicity.
Results
Baseline characteristics. Summarized in Table 1, the
aseline characteristics of the group were similar to those of
ther BTT studies and reflect the composition of the heart
ransplant waiting lists at the participating institutions.
ost patients were men (86%), and the mean age was 48.5
ears (range 20 to 75 years). The cause of heart failure was
diopathic in 22 patients (44%), ischemic in 20 patients
40%), familial in 5 patients (10%), and myocarditis in 3
atients (6%). All patients had New York Heart Association
unctional class IV symptoms. Baseline clinical conditions
ere used to categorize patients according to INTERMACS
rofiles, which classify the severity of heart failure of
atients (9). Of the patients, 11 (22%) were in profile 2
progressive decline), 35 (70%) were in profile 3 (stable but
notrope dependent), and 4 (8%) were in profile 4 (recurrent
dvanced heart failure). All were receiving inotropes. So
hy were these not profile 3? Were they not deemed
notrope dependent? All patients were receiving intravenous
notropic medications, and 4 (8%) of the patients were also
eing supported by an intra-aortic balloon pump. Cardiac
unction was considerably impaired in the group, on the
asis of analysis of hemodynamic parameters. Pre-operative
isk factors are summarized in Table 2.
utcomes. The survival to heart transplantation; myocar-
ial recovery and HVAD pump explant; or ongoing support
t 6, 12, and 24 months after implant was 90%, 84%, and
9%, respectively (Figs. 2 and 3). The SHFM estimated
urvival (mean  SEM) of this cohort if medical therapy
as continued was 73  3% at 180 days, 58  4% at 1 year,
nd 40  4% at 2 years (Fig. 3). Twenty of the 50 patients
ad a 50% estimated mortality at 1 year. The estimated
azard ratio for LVAD therapy, with the SHFM as a virtual
Pre-Operative Risk FactorsTable 2 Pre-Operative Risk Factors
Parameter Patients (n)
Inotropic support 50
Previous myocardial infarction 10
Coronary angioplasty 13
Previous sternotomy 6
Arrhythmias 25
Implantable cardioverter-defibrillator 32
Pacemaker 9
Moderate-severe right ventricular dysfunction 19
Hypertension 15Diabetes 7ontrol arm, was 0.33 at 180 days, 0.29 at 1 year, and 0.26
t 2 years (all p values 0.001) (Fig. 3).
The median duration on HVAD pump support during
he trial interval was 322 days (range 12 to 847 days), mean
uration of HVAD pump support was 348 days, and the
umulative support time was 47.8 years. There were no
echanical failures of the HVAD system. As of May 1,
010, 20 (40%) patients had undergone heart transplant, 4
8%) recovered myocardial function and had the device
xplanted, and support was ongoing in 16 (32%). The
edian time to heart transplant was 267 days (range 45 to
69 days). Nine patients (18%) died during support at a
edian duration of 94 days (range 13 to 515 days). The
Figure 2 Competing Outcomes
Competing outcomes from the time of implant to 24 months.
Figure 3 Actuarial Success Rates With HVAD and
Predicted Survival Rates Based on the SHFM
Actuarial success rates with HeartWare Ventricular Assist Device (HVAD) and
prediction of survival with continued medical therapy (on the basis of the Seat-
tle Heart Failure Model [SHFM]).
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n  3), and hemorrhagic stroke (n  3). Hemodynamic
ariables improved significantly after the HVAD was im-
lanted (Table 3). At baseline, the mean cardiac index was
.94  0.54 l/min/m2; it increased to 2.9  0.76 l/min/m2
(p  0.001) at 24 h and 2.83  0.63 l/min/m2 at 48 h (p 
0.0001) after the implant. The mean pulmonary capillary
wedge pressure decreased from 23.7  6.5 mm Hg at
baseline to 15.0  3.6 mm Hg (p  0.001) at 24 h and 15.5 
3.4 mm Hg (p  0.0001) at 48 h. The HVAD pump flow
index at 24 and 48 h after implant was 3.32  0.6 l/min/m2
and 3.14  0.54 l/min/m2, respectively; both values were
significantly greater (p  0.0001) than the baseline cardiac
index (1.94  0.54 l/min/m2). There were no significant
hanges in the central venous pressure or mean arterial
lood pressure.
Serial laboratory analyses for the entire cohort from
aseline to 6 months are listed in Table 4. Measures of renal
nd hepatic function were abnormal after the implant
urgery but returned to normal ranges by 2 weeks. A
ost-implant decrease in hemoglobin and hematocrit levels,
econdary to operative bleeding, returned to normal ranges
y 3 months. Anticoagulation therapy was the cause for
levated activated partial thromboplastin times. The mean
NR reached therapeutic range by 14 days and remained
ithin that range at 180 days.
Hemodynamic Changes From Baseline to 24 anTable 3 Hemodynamic Changes From Basel
Baseline 24 h
CI (l/min/m2) 1.94 0.54 2.9 0.76
MAP (mm Hg) 76.7 10.6 79.8 11.6
PCWP (mm Hg) 23.7 6.5 15 3.6
HVAD flow index
(l/min/m2)
N/A 3.32 0.6
Values are mean  SD.
CI  cardiac index; HVAD  HeartWare Ventricular Assist Device; M
Laboratory Values From Baseline to 6 Months After HVAD ImplantTable 4 Laboratory Values From Baseline to 6 Months After HV
Baseline 1 Week
Sodium (mEq/l) 136.1 4.7 137.6 8.5
Creatinine (mg/dl) 1.3 0.5 1.1 0.6
BUN (mg/dl) 28.9 15.6 24.4 19.5
LDH (IU/l) 325 176 802 756
ALT (IU/l) 63.6 127.0 89.1 191.0
AST (IU/l) 75.8 132.0 73.6 91.0
Bilirubin (mg/dl) 1.5 1.0 2.6 3.8
Hgb (mg/dl) 12.4 2.0 10.4 1.2
HCT (%) 36.8 6.0 31.5 3.9
PFH (mg/dl) 10.1 13.8 13.7 45.2
APTT (s) 39.7 10.6 54.8 20.0
INR 1.6 0.6 2.3 1.4
Platelets ( 109/l) 243 102 201 106
WBC (109/l) 8.6 2.9 11.4 4.9Values are mean  SD.
WBC  white blood cells; other abbreviations as in Tables 1 and 3.The mean hospital stay was 45 days; of this time, 13.1 
.3 days were in the intensive care unit, 16.4  12.6 days in
step-down unit, and 15.4  10.2 days in a regular floor
nit. Of the 50 patients, 47 (94%) were discharged from the
ospital; the cumulative outpatient support time was 42.6
ears. There were 53 readmissions to the hospital for various
edical reasons. The readmission rate for medical compli-
ations was 1.24 admissions/patient-year, which is a 74%
eduction when compared with the average admission rate
f this group for the year before their HVAD implants.
atients discharged from the hospital recorded pump per-
ormance parameters, which showed that the mean pump
peed was 2,709  164 rpm and the mean flow was 6.4 
.8 l/min at 4.6  0.7 W.
dverse events. There were 92 adverse events reported for
9 patients during a cumulative support time of 47.8 years
1.92 events/patient-year) (Table 5). Eleven of the 50
atients (22%) did not experience any adverse event during
he follow-up period. The most common adverse events
ere infection-related. Infection of the driveline exit site
0.20 events/patient-year) did not cause any deaths and
ccurred mainly after 30 days of support. Five patients
10%) developed sepsis, and sepsis was the cause of death in
patients. The causes of sepsis were varied (pneumonia: 2,
ungal sepsis: 1, bacteremia: 1, and driveline exit site: 1) and
ccurred between 48 h and 970 days after implant. Bleeding
h of HVAD Support24 and 48 h of HVAD Support
p Value
line vs. 24 h) 48 h
p Value
(Baseline vs. 48 h)
0.0001 2.83 0.63 0.0001
NS 82.4 10.5 0.01
0.001 15.5 3.4 0.0001
0.0001 3.14 0.54 0.0001
ean arterial pressure, PCWP  pulmonary capillary wedge pressure.
mplant
2 Weeks 3 Months 6 Months
136.8 6.4 138.6 3.3 139.4 2.5
1.1 0.7 1.0 0.3 1.2 0.3
21.9 21.0 19.7 9.9 25.5 15.8
628 675 467 520 338.6 157.7
73.5 104 30 10 34.6 14.0
57.3 63.4 23.1 13.7 29.5 17.3
1.4 1.2 0.8 0.5 0.8 0.4
10.9 4.4 12.5 1.8 12.9 2.6
31.0 3.2 37.6 4.5 37.6 6.0
7.8 15.7 7.1 7.1 7.0 8.5
50.2 17.3 46.6 19.5 49.1 13.4
2.0 0.9 2.7 0.7 2.8 0.7
374 169 269 66 223 54
12.4 4.5 7.8 1.9 7.0 1.3d 48ine to
(BaseAD I
ent rate
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hospital stay occurred primarily within the first 30 days after
implant (0.33 events/patient-year) and were observed less
frequently after 30 days (0.11 events/patient-year). Ventric-
ular arrhythmias were uncommon (0.04 events/patient-
year). Ischemic stroke occurred in only 2 patients within the
first 30 days. Hemorrhagic stroke occurred in 4 patients—all
after 30 days, and 3 of these patients died. The INRs at the
time of the hemorrhagic stroke were 3.1, 2.9, 2.2, and 3.5.
Other neurologic events included 3 transient ischemic
attacks. Devices were exchanged in 7 patients. In 2 patients
(4%), the device was exchanged due to manufacturing
variability of the thrust bearings. Four devices (8%) were
exchanged because thrombus, suspected to be from the LV,
entered the pump. The 4 exchanges due to thrombus
occurred at 3, 71, 97, and 560 days. No clot was identified
by pre-operative echocardiography in these cases. At the
time of implant after LV apex coring, the LV was visually
examined for thrombus—which, if found, was removed.
However, for the early exchange, a remaining thrombus in
the left heart is likely; this patient was receiving IV heparin
Adverse EventsTable 5 Adverse Events
Adverse Event
Overall
(Support Duration 47.8 Patient-Yrs)
Patients With Event,
n (%)
Number of
Events
Event
Rate
Infection
Localized nondevice related 7 (14%) 7 0.15
Sepsis 5 (10%) 5 0.10
Driveline exit site 9 (18%) 10 0.20
Bleeding
Surgery 10 (20%) 11 0.23
Transfusion 2 U 2 (4%) 2 0.04
Hospital stay 3 (6%) 3 0.06
Ventricular arrhythmias 2 (4%) 2 0.04
Neurological dysfunction
Ischemic stroke 2 (4%) 2 0.04
Hemorrhagic stroke 4 (8%) 4 0.08
TIA 2 (4%) 3 0.06
Pulmonary dysfunction 8 (16%) 9 0.19
Device replacement 7 (14%) 7 0.15
Manufacturing defect 2 (4%) 2 0.04
Left heart embolus 4 (8%) 4 0.08
Inflow occlusion 1 (2%) 1 0.02
Pleural effusion 6 (12%) 7 0.15
Right heart failure
RVAD 3 (6%) 3 0.06
IV inotropes 3 (6%) 3 0.06
Renal dysfunction 5 (10%) 5 0.10
Hepatic dysfunction 3 (6%) 3 0.06
Hemolysis 1 (2%) 1 0.02
Heart failure 3 (6%) 3 0.06
Chest pain 1 (2%) 1 0.02
Femoral embolism 2 (4%) 2 0.04
On the basis of Inter-Agency Registry for Mechanically Assisted Circulatory Support definitions. Ev
IV  intravenous; RVAD  right ventricular assist device; TIA  transient ischemic attack.with a partial thromboplastin time of 54 s. The other 3patients were taking warfarin, with INRs of 2.6, 2.7, and
3.2. In 2 of them, platelet inhibitors were withdrawn for
minor (nose) bleeding. In 1 patient (2%), the device was
exchanged due to complications of surgical implantation.
Renal, hepatic, or pulmonary dysfunction was uncommon,
and end-organ function improved in most patients (Table 5).
However, severe end-organ dysfunction did occur in the 3
patients who died of multiple-organ failure. Right heart
failure occurred in 6 patients (12%); 3 of these patients
required right ventricular assist device (RVAD) support,
and 3 received intravenous inotropic support for 14 days.
A Levitronix CentriMag pump (Levitronix, Waltham,
Massachusetts) was used as an RVAD on all 3 patients. One
patient died during RVAD (RVAD support 4 days) sup-
port, 2 RVADs were electively removed after 7 and 25 days
of support, and 1 of these patients expired on post-operative
day 84.
Quality of life and neurocognitive function. The results
of complete paired data from the KCCQ at baseline and at
intervals of 1 month (n  28), 3 months (n  27), and 6
months (n  15) are shown in Figure 4. For this group,
0–30 Days
Support Duration 4.0 Patient-Yrs)
>30 Days
(Support Duration 43.8 Patient-Yrs)
tients With
Event
Number of
Events
Event
Rate
Patients With
Event
Number of
Events
Event
Rate
2 2 0.50 5 5 0.11
1 1 0.25 4 4 0.09
0 0 0.00 9 10 0.21
8 8 2.00 3 3 0.07
1 1 0.25 1 1 0.02
1 1 0.25 2 2 0.05
1 1 0.25 1 1 0.02
2 2 0.50 0 0 0.00
0 0 0.00 4 4 0.09
0 0 0.00 2 3 0.07
7 8 2.00 1 1 0.02
4 4 1.00 3 3 0.07
2 2 0.50 0 0 0.00
1 1 0.25 3 3 0.07
1 1 0.25 0 0 0.00
5 5 1.25 1 2 0.05
2 2 0.50 1 1 0.02
1 1 0.25 2 2 0.05
5 5 1.25 0 0 0.00
1 1 0.25 2 2 0.05
1 1 0.25 0 0 0.00
1 1 0.25 2 2 0.05
0 0 0.00 1 1 0.02
1 1 0.25 1 1 0.02
is number of events/patient-year.(
Pahealth-related quality of life improved for every subscale of
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March 22, 2011:1375–82 Multicenter Evaluation of Intrapericardial LVADthe KCCQ. The improvement in symptom burden, quality of
life, physical limitations, and overall functional status across all
testing periods for all patients was statistically significant (p 
0.05). The largest improvements were observed in the first 30
days after the HVAD implant. There were no statistically
significant declines in neurocognition for any of the cognitive
domains from baseline to 1, 3, and 6 months after the implant.
Significant improvements were found for recognition memory
at 3 months after surgery (p 0.006), Trail Making Test Part
A at 3 months after surgery (p 0.039) and at 6 months after
urgery (p  0.001), and Trail Making Test Part B at 6
onths after surgery (p  0.002) as compared with values
efore the implant.
iscussion
ver the past decade, survival rates in the BTT population
ave steadily increased because of improvements in patient
election and management and the introduction of rotary
lood pump technology (10,11). The results of this study
ndicate that patients with severe heart failure can be bridged
o heart transplant with a small, levitated continuous-flow
VAD that is implanted within the pericardial space and that
Figure 4 Quality of Life Measures
Results of the Kansas City Cardiomyopathy Questionnaire (KCCQ) subscales befor
Device support. A higher score represents improved self-report for a domain. *Starovides full circulatory support. Most patients recovered from the negative effects of chronic heart failure during HVAD
ump support, as evidenced by improvements in measures of
nd-organ function, quality of life, and neurocognitive func-
ion. All patients who have continued with HVAD pump
upport are outpatients, and they have had few medical
roblems requiring hospital readmission. Patients who were
ridged to a heart transplant had a 6-month survival of 95%
fter transplant. The positive results achieved in this trial
esulted from the ability of the device to restore normal
irculation and the low incidence of life-threatening adverse
vents. This is demonstrated again in the 93% 6-month
urvival in patients 60 years of age and older (n  14).
The small size of the HVAD pump and its integrated inflow
annula allow for its placement within the pericardial space,
hus eliminating the need to create an abdominal pocket as is
equired for most other LVAD systems. Avoiding entry into
he abdomen for LVAD implantation might reduce the
otential for surgical bleeding and device-related infection.
he abdominal surgery has been a source of serious device-
elated infections in some LVAD technologies, and it is
ssociated with significant morbidity and mortality (12). In this
tudy, there were no cases of device-related abdominal com-
lications. Device-related infections have been reduced with
ant surgery and at 1 month and 3 and 6 months of HeartWare Ventricular Assist
lly significant improvement in KCCQ score at p  0.05.e impl
tisticahe pericardial placement of the HVAD, although the need for
1382 Strueber et al. JACC Vol. 57, No. 12, 2011
Multicenter Evaluation of Intrapericardial LVAD March 22, 2011:1375–82skin penetration of the driveline continues to be a source of
infectious complications.
Post-operative bleeding complications have been a lead-
ing cause of morbidity, when LVADs were first implanted
30 years ago. The principal factors contributing to bleeding
are pre-existing coagulation disorders of patients caused by
renal and hepatic dysfunction, the extensive surgery required
for device placement, and clotting factor depletion that
results from the use of cardiopulmonary bypass. Experi-
enced clinicians have made progress in optimizing the
pre-operative coagulation status, but the extent of improve-
ment is limited by the underlying low cardiac output of
patients. Implantation of the HVAD pump minimizes the
amount of tissue damage and cardiopulmonary bypass time.
These factors might contribute to the low incidence of
postoperative bleeding observed in this study.
Early in the trial, a series of HVAD pumps developed
unexplained thrombi. After a review of the clinical and
technical data, it was determined that manufacturing vari-
ability of the thrust bearings resulted in an area of reduced
flow that could have been more prone to thrombus forma-
tion. In these 2 cases, a thrombus formed within the HVAD
that was resistant to anticoagulation and thrombolytic
therapy, necessitating device replacement. This problem was
resolved by optimizing the manufacturing process and no
further events have occurred in over 450 additional im-
plants. The wide-blade impeller design of the HVAD pump
seems to be durable and hemocompatible, demonstrating
effective support in patients for over 1,000 days without
failure of any internal components of the device.
Study limitations. This study is limited mainly by its
noncontrolled and nonblinded methods. In this severely ill
patient population, randomization to no therapy or contin-
ued medical therapy is not appropriate, considering the
established superiority of LVAD therapy. In addition, some
bias might occur in patient selection, even though study
inclusion and exclusion criteria define the population. Al-
though the participating centers are all experienced with
LVAD therapy, center variability in the supportive care of
patients also cannot be completely standardized. Although
the study was designed as a BTT trial, the low incidence of
heart transplant within the first 180 days is in contrast other
BTT trials. The prolonged waiting times to locate a donor
heart in Australia and Europe reflect the reality of donor
shortage in these countries. That most patients had ongoing
support for more than 1 year allowed for analysis of median
term use of this novel device. However, the follow-up of
continuous variables is affected by the attrition of patients
who receive heart transplants or undergo device explant.
The use of a virtual control arm by predicting survival on
medical management with the SHFM does not reach the
statistical impact of a 2-armed randomized trial. However,
given the large differences in predicted and observed sur-
vival, it is evident that there is a survival benefit with the use
of LVADs. These data strongly suggest that patients inend-stage heart failure should be evaluated for the implan-
tation of a continuous flow blood pump.
Conclusions
The HVAD system provided safe and effective circulatory
support in a population of end-stage heart failure patients.
During HVAD system support, hemodynamic status, qual-
ity of life, and neurocognitive function improved for the
majority of patients. In this first clinical study with a
miniaturized LVAD placed in the pericardial space, the
2-year survival rate was similar to that of heart transplant,
which suggests that this long-term therapy is promising for
the heart failure population.
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APPENDIX
For study inclusion and exclusion criteria,
please see the online version of this article.
